Terminated × Has results × Myeloproliferative Disorders × Clear all FLUBUTBI
Phase 3 Terminated
53 enrolled 11 charts
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Phase 2 Terminated
73 enrolled 25 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Phase 3 Terminated
177 enrolled 15 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Phase 2 Terminated
2 enrolled 12 charts
FREEDOM
Phase 3 Terminated
38 enrolled 23 charts
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Phase 2 Terminated
3 enrolled 12 charts
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Phase 2 Terminated
74 enrolled 40 charts
Study of INCB053914 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
97 enrolled 40 charts
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Phase 2 Terminated
27 enrolled 28 charts
OPTIC-2L
Phase 3 Terminated
44 enrolled 22 charts
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Phase 2 Terminated
12 enrolled 15 charts
PAC326
Phase 3 Terminated
311 enrolled 12 charts
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Phase 2/3 Terminated
40 enrolled 10 charts
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Phase 3 Terminated
327 enrolled 11 charts
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
Phase NA Terminated
1 enrolled 3 charts
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase 2 Terminated
442 enrolled 17 charts
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
Phase 2 Terminated
4 enrolled 5 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
12 enrolled 14 charts
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Phase 2 Terminated
19 enrolled 19 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase NA Terminated
1 enrolled 7 charts
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
Phase 2 Terminated
13 enrolled 10 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
Phase NA Terminated
16 enrolled 6 charts
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
Phase 2 Terminated
7 enrolled 6 charts
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Phase 1/2 Terminated
4 enrolled 8 charts
REGKINE
Phase NA Terminated
26 enrolled 7 charts
REGALE
Phase NA Terminated
24 enrolled 7 charts
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Phase 2 Terminated
4 enrolled 11 charts
Aflibercept in Treating Patients With Myelodysplastic Syndromes
Phase 2 Terminated
18 enrolled 4 charts
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Phase 3 Terminated
307 enrolled 11 charts
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
Phase NA Terminated
6 enrolled 13 charts
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
Phase 3 Terminated
151 enrolled 17 charts
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts
Imatinib Mesylate in Treating Patients With Myelofibrosis
Phase 2 Terminated
10 enrolled 6 charts